RxDoctor Payments DataLook up a doctor →

Thomas Cawley, PA

Medical · Richmond, VANPI 1568866010

Payments from drug & device makers

$8,453in general payments, 2019–2025

Across 549 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$871
  • Amgen$622
  • Lilly USA, LLC$586
  • Novo Nordisk$570
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$348
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,453 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$117,145
Medicare patients
310
Services billed
3,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$39,651
JardianceEmpagliflozin17$29,743
EliquisApixaban23$25,982
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,827
FarxigaDapagliflozin Propanediol11$17,729
OzempicSemaglutide27$16,382
LinzessLinaclotide17$14,917
JanuviaSitagliptin Phosphate18$6,670
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,855
Rosuvastatin Calcium267$2,870
Atorvastatin Calcium330$2,455
Duloxetine Hcl93$2,170
Valsartan72$1,967
SynthroidLevothyroxine Sodium18$1,963
Levothyroxine Sodium147$1,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$586$39,65134 claims
Boehringer IngelheimJardiance$135$29,74317 claims
PfizerEliquis$302$25,98223 claims
GSKTrelegy Ellipta$220$22,82724 claims
AstraZenecaFarxiga$871$17,72911 claims
AbbVieLinzess, Synthroid$1,767$16,88135 claims
Novo NordiskOzempic$570$16,38227 claims
MerckJanuvia$42$6,67018 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$1,542147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.

Other medical in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →